TNG:EPA
Transgene SA
0,70 €
arrow_downward
-1,96%(-0,014) 1D
2 қаз., 17:35:08 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
0,70 €
High
0,70 €
Low
0,69 €
Mkt. cap
196,62 млн
Avg. vol.
140,11 м.
Volume
166,60 м.
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 млн
No. of employees
160
Open
0,70 €
High
0,70 €
Low
0,69 €
Mkt. cap
196,62 млн
Avg. vol.
140,11 м.
Volume
166,60 м.
52-wk high
1,50 €
52-wk low
0,69 €
EPS
-0,17 €
Shares outstanding
278,56 млн
No. of employees
160
News stories
From web sources and news partners
MarketBeat
·
25 минут бұрын
Zoom Communications, Inc. (NASDAQ:ZM) Stock Has Consensus Target Price of $113.62 According to Analysts
Simply Wall Street
·
1 сағат бұрын
Will Product Recalls Change ICU Medical (ICUI) Stock Narrative
AD HOC NEWS
·
1 сағат бұрын
Ripple Unlocks Another Billion XRP as Evernorth Prepares Nasdaq Listing Under XRPN
WSJ
·
10 сағат бұрын
Nasdaq Leads Stocks Higher as Hiring Softens
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA